Abstract:

Breast cancer, as the most common malignant tumors among women globally, has seen an increasing incidence rate year by year, posing a serious threat to women's health. Traditional treatment methods for breast cancer still have many limitations. Antibody-drug conjugates (ADCs) are a new type of targeted drugs for treating breast cancer, which have shown remarkable efficacy in the treatment of HER2-positive breast cancer. At the same time, important progress has also been made in the treatment of advanced triple-negative breast cancer (TNBC) and some breast cancers with low HER2 expression, providing more options for people with different molecular subtypes of breast cancer. This article mainly elaborates and discusses the latest progress after the treatment with ADC drugs for breast cancer and the future development directions.

Key words: Antibody-drug conjugates drugs, Breast cancer, Research progress